|
1
|
Jinushi M: The role of innate immune
signals in antitumor immunity. Oncoimmunology. 1:189–194. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akira S and Hemmi H: Recognition of
pathogen-associated molecular patterns by TLR family. Immunol Lett.
85:85–95. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hidmark A, von Saint Paul A and Dalpke AH:
Cutting edge: TLR13 Is a Receptor for Bacterial RNA. J Immunol.
189:2717–2721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang YJ, Wu MS, Lin JT and Chen CC:
Helicobacter pylori-induced invasion and angiogenesis of
gastric cells is mediated by cyclooxygenase-2 induction through
TLR2/TLR9 and promoter regulation. J Immunol. 175:8242–8252. 2005.
View Article : Google Scholar
|
|
5
|
Droemann D, Albrecht D, Gerdes J, Ulmer
AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P and Goldmann T:
Human lung cancer cells express functionally active Toll-like
receptor 9. Respir Res. 6:12005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa
T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander
KS: Toll-like receptor 9 agonists promote cellular invasion by
increasing matrix metalloproteinase activity. Mol Cancer Res.
4:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takala H, Kauppila JH, Soini Y, Selander
KS, Vuopala KS, Lehenkari PP, Saarnio J and Karttunen TJ: Toll-like
receptor 9 is a novel biomarker for esophageal squamous cell
dysplasia and squamous cell carcinoma progression. J Innate Immun.
3:631–638. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kauppila JH, Takala H, Selander KS,
Lehenkari PP, Saarnio J and Karttunen TJ: Increased Toll-like
receptor 9 expression indicates adverse prognosis in oesophageal
adenocarcinoma. Histopathology. 59:643–649. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Väisänen MR, Väisänen T, Jukkola-Vuorinen
A, Vuopala KS, Desmond R, Selander KS and Vaarala MH: Expression of
toll-like receptor-9 is increased in poorly differentiated prostate
tumors. Prostate. 70:817–824. 2010.PubMed/NCBI
|
|
10
|
Ronkainen H, Hirvikoski P, Kauppila S,
Vuopala KS, Paavonen TK, Selander KS and Vaarala MH: Absent
Toll-like receptor-9 expression predicts poor prognosis in renal
cell carcinoma. J Exp Clin Cancer Res. 30:842011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jukkola-Vuorinen A, Rahko E, Vuopala KS,
Desmond R, Lehenkari PP, Harris KW and Selander KS: Toll-like
receptor-9 expression is inversely correlated with estrogen
receptor status in breast cancer. J Innate Immun. 1:59–68. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ilvesaro JM, Merrell MA, Swain TM,
Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like
receptor-9 agonists stimulate prostate cancer invasion in vitro.
Prostate. 67:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang
Y, Zhou Y, Zhou H and Wen Z: TLR9 signaling promotes tumor
progression of human lung cancer cell in vivo. Pathol Oncol Res.
15:623–630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sandholm J, Kauppila JH, Pressey C,
Tuomela J, Jukkola-Vuorinen A, Vaarala M, Johnson MR, Harris KW and
Selander KS: Estrogen receptor-alpha and sex steroid hormones
regulate Toll-like receptor-9 expression and invasive function in
human breast cancer cells. Breast Cancer Res Treat. 132:411–419.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kakonen SM, Selander KS, Chirgwin JM, Yin
JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y and Guise TA:
Transforming growth factor-beta stimulates parathyroid
hormone-related protein and osteolytic metastases via Smad and
mitogen-activated protein kinase signaling pathways. J Biol Chem.
277:24571–24578. 2002. View Article : Google Scholar
|
|
16
|
Flatt T, Heyland A, Rus F, Porpiglia E,
Sherlock C, Yamamoto R, Garbuzov A, Palli SR, Tatar M and Silverman
N: Hormonal regulation of the humoral innate immune response in
Drosophila melanogaster. J Exp Biol. 211:2712–2724. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tuomela J, Sandholm J, Karihtala P,
Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C,
Harkonen P, Harris KW, Graves D, Auvinen PK, Soini Y,
Jukkola-Vuorinen A and Selander KS: Low TLR9 expression defines an
aggressive subtype of triple-negative breast cancer. Breast Cancer
Res Treat. 135:481–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vincent IE, Zannetti C, Lucifora J, Norder
H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trepo C, Hasan U
and Chemin I: Hepatitis B virus impairs TLR9 expression and
function in plasmacytoid dendritic cells. PLoS One. 6:e263152011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu SL, Chan PK, Wong CK, Szeto CC, Ho SC,
So K, Yu MM, Yim SF, Cheung TH, Wong MC, Cheung JL, Yeung AC, Li EK
and Tam LS: Antagonist-mediated down-regulation of toll-like
receptors increases the prevalence of human papillomavirus
infection in systemic lupus erythematosus. Arthritis Res Ther.
14:R802012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
González-Reyes S, Fernandez JM, González
LO, Aguirre A, Suarez A, González JM, Escaff S and Vizoso FJ: Study
of TLR3, TLR4, and TLR9 in prostate carcinomas and their
association with biochemical recurrence. Cancer Immunol Immunother.
60:217–226. 2011.PubMed/NCBI
|
|
21
|
Ilvesaro JM, Merrell MA, Li L, Wakchoure
S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS,
Harris KW and Selander KS: Toll-like receptor 9 mediates CpG
oligonucleotide-induced cellular invasion. Mol Cancer Res.
6:1534–1543. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakai Y and Nonomura N: Inflammation and
prostate carcinogenesis. Int J Urol. Jul 31–2012.(Epub ahead of
print). View Article : Google Scholar
|
|
23
|
Kundu SD, Lee C, Billips BK, Habermacher
GM, Zhang Q, Liu V, Wong LY, Klumpp DJ and Thumbikat P: The
toll-like receptor pathway: a novel mechanism of infection-induced
carcinogenesis of prostate epithelial cells. Prostate. 68:223–229.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di JM, Pang J, Sun QP, Zhang Y, Fang YQ,
Liu XP, Zhou JH, Ruan XX and Gao X: Toll-like receptor 9 agonists
up-regulates the expression of cyclooxygenase-2 via activation of
NF-kappaB in prostate cancer cells. Mol Biol Rep. 37:1849–1855.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Di JM, Pang J, Pu XY, Zhang Y, Liu XP,
Fang YQ, Ruan XX and Gao X: Toll-like receptor 9 agonists promote
IL-8 and TGF-beta1 production via activation of nuclear factor
kappaB in PC-3 cells. Cancer Genet Cytogenet. 192:60–67. 2009.
View Article : Google Scholar : PubMed/NCBI
|
